The synthesis of retatrutide, a novel dual agonist targeting both GLP-1 and GIP receptors, requires a complex multi-step synthetic process. Initial routes focused on protein portion coupling, utilizing solid-phase creation methodologies to build the long protein sequence. Subsequent research has explored alternative approaches, including enzymatic